Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
SEK 0.13
(2.42%)
SEK 0.13
(2.42%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -31.92 Million SEK | -231.3% |
| 2022 | -9.63 Million SEK | 66.15% |
| 2021 | -28.46 Million SEK | -126.81% |
| 2020 | -12.55 Million SEK | -1102.2% |
| 2019 | -1.04 Million SEK | -875.7% |
| 2018 | -107 Thousand SEK | 99.99% |
| 2017 | -1.59 Billion SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -24 Million SEK | 24.82% |
| 2024 Q2 | -19.47 Million SEK | 18.86% |
| 2023 Q1 | -4.27 Million SEK | 55.67% |
| 2023 Q3 | -25.21 Million SEK | -45.69% |
| 2023 FY | -31.92 Million SEK | -231.3% |
| 2023 Q4 | -31.92 Million SEK | -26.6% |
| 2023 Q2 | -17.3 Million SEK | -305.17% |
| 2022 Q3 | -15.57 Million SEK | -318.82% |
| 2022 Q1 | -16.7 Million SEK | 41.33% |
| 2022 FY | -9.63 Million SEK | 66.15% |
| 2022 Q4 | -9.63 Million SEK | 38.13% |
| 2022 Q2 | -3.71 Million SEK | 77.73% |
| 2021 Q1 | -58.94 Million SEK | -369.64% |
| 2021 FY | -28.46 Million SEK | -126.81% |
| 2021 Q4 | -28.46 Million SEK | 28.2% |
| 2021 Q3 | -39.64 Million SEK | 20.98% |
| 2021 Q2 | -50.17 Million SEK | 14.89% |
| 2020 FY | -12.55 Million SEK | -1102.2% |
| 2020 Q4 | -12.55 Million SEK | 0.0% |
| 2020 Q1 | 2.49 Million SEK | 0.0% |
| 2019 FY | -1.04 Million SEK | -875.7% |
| 2018 FY | -107 Thousand SEK | 99.99% |
| 2017 FY | -1.59 Billion SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | -50.415% |
| Amniotics AB (publ) | -5.63 Million SEK | -466.886% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -1377.418% |
| BioArctic AB (publ) | -606.58 Million SEK | 94.737% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 691.241% |
| Genovis AB (publ.) | -43.94 Million SEK | 27.341% |
| LIDDS AB (publ) | -13.51 Million SEK | -136.286% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 159.987% |
| OncoZenge AB (publ) | -12.62 Million SEK | -152.847% |
| Saniona AB (publ) | 40.44 Million SEK | 178.935% |
| Simris Alg AB (publ) | 85.07 Million SEK | 137.528% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 90.43% |
| AcouSort AB (publ) | -23.98 Million SEK | -33.107% |
| Active Biotech AB (publ) | -33.2 Million SEK | 3.834% |
| Camurus AB (publ) | -1.16 Billion SEK | 97.26% |
| Cantargia AB (publ) | -139.74 Million SEK | 77.154% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -3359.047% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 61.874% |
| Mendus AB (publ) | -96.29 Million SEK | 66.844% |
| Kancera AB (publ) | -45.69 Million SEK | 30.126% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 61.16% |
| Lipum AB (publ) | -8.46 Million SEK | -277.165% |
| NextCell Pharma AB | -46.79 Million SEK | 31.766% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 119.224% |
| Xintela AB (publ) | -7.8 Million SEK | -308.849% |
| Ziccum AB (publ) | -2.13 Million SEK | -1394.01% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -8.658% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -67.508% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 76.889% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 75.345% |
| CombiGene AB (publ) | -101.44 Million SEK | 68.526% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 61.105% |
| Intervacc AB (publ) | -88.16 Million SEK | 63.785% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 36.173% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 36.062% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 255.666% |
| Corline Biomedical AB | -17.01 Million SEK | -87.673% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 61.875% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 18.93% |
| Aptahem AB (publ) | 2.9 Million SEK | 1197.66% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 90.298% |
| Fluicell AB (publ) | -2.76 Million SEK | -1055.519% |
| Biovica International AB (publ) | -58.73 Million SEK | 45.644% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 29.392% |
| Abliva AB (publ) | -57.24 Million SEK | 44.223% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 83.602% |
| 2cureX AB (publ) | -13.4 Million SEK | -138.208% |
| I-Tech AB | -83.26 Million SEK | 61.655% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 123.701% |
| Cyxone AB (publ) | -16.67 Million SEK | -91.524% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 42.871% |
| Biosergen AB | -1.88 Million SEK | -1595.539% |
| Nanologica AB (publ) | -9.38 Million SEK | -240.083% |
| SynAct Pharma AB | -61.75 Million SEK | 48.303% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -49.087% |
| BioInvent International AB (publ) | -236.3 Million SEK | 86.489% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -141.338% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 52.291% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -516.242% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -53.547% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -974.26% |